Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | 2025 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -241.09K | 32.75% |
| EBITDA | -257.26K | 28.25% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €945.05K |
Number of shares | 25.1M |
52-week high/low | €0.29 - €0.0359 |
| Dividends | No |
Beta | 3.01 |
P/E ratio | -4.20 |
PEG ratio | -0.19 |
P/B ratio | 2.07 |
P/S ratio | 0.00 |
Company profile
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
| Name | 2CUREX AB SEK-,10 Aktie |
| CEO | Nathaniel Hutley |
| Headquarters | Landskrona,
Denmark |
| Website | |
| IPO | 11/24/2017 |
| Employees | 14 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Sto | 2CUREX.ST |
Frankfurt | 2QE.F |
Stockholm | 2CUREX.ST |
München | 2QE.MU |